From one 328 to another... I'm long with my largest purchase at 1.80. Before recent purchases at 12 when I let some short puts get exercised my basis was about 2.2. Now its 5+ on the actual position (negative with many rounds of CC and short put premiums and selling many shares along the way). I think the upside potential makes this longshot a reasonable position in the highest risk portion of my biotech portfolio but betting the bank is not my style. I am not a fan of Missling or the BOD/college buddies.
It's possible Rett parents could exert pressure. I feel Anavex will try to get approval after Excellence but not based on RS001 and Avatar alone...I also feel they will try to get approval for all ages at that point (of course assuming good Excellence results).
Aussie parents of young patients may have more less luck with the FDA than with the TGA - another reason for Missling to add some US sites and get the trial enrolled already. Unlike Duchenne where patients were very eloquent despite their young age, Rett patients can not 'take the stand' to beg for approval.
Aduhelm was a mistake and I am sure they realize that now. Most of the time, the FDA follows its own guidance.
News 
Market Data 
Discover 
AI
